Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study
Launched by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST · May 20, 2020
Trial Information
Current as of August 28, 2025
Unknown status
Keywords
ClinConnect Summary
Streptococcus pneumoniae (the pneumococcus) is an important cause of pneumonia, meningitis and bacteraemia worldwide. The prevention of invasive pneumococcal disease (IPD) by immunisation has been a key public health priority. Conjugate vaccines have a good record of eradicating carriage of bacteria as well as protecting against disease because they evoke a T-cell dependent response. For this reason, they are also efficacious in children less than 2 years of age. The first pneumococcal conjugate vaccine, Prevenar 7, was licensed in the UK in 2001 and was added to the routine UK childhood im...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All children aged 4 years or under, attending the recruitment sites during the recruitment period will be invited to participate through their parents or legal guardian.
- Exclusion Criteria:
- • One child per family
- • Children with obstructed nasal passages
About University Hospital Southampton Nhs Foundation Trust
University Hospital Southampton NHS Foundation Trust is a leading academic medical center located in the UK, renowned for its commitment to innovative healthcare and research. As a prominent sponsor of clinical trials, the Trust integrates cutting-edge research with clinical practice to advance medical knowledge and improve patient outcomes. With a diverse range of specialties, including cardiology, oncology, and pediatrics, the Trust actively collaborates with academic institutions and industry partners to conduct high-quality trials that adhere to rigorous ethical standards and regulatory guidelines. Its multidisciplinary approach ensures comprehensive patient care while fostering an environment of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southampton, Hampshire, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials